The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer

Abstract

Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.

Keywords: DNA damage repair; NSCLC; immunotherapy; radiotherapy; umbrella study.